Vetnuus | August 2026 7 *Over the other JAK enzymes in in vitro assays. **In a canine interleukin-31 (cIL-31)-induced pruritus model. References: 1. Kowalski T, Schuette S. The second-generation Janus kinase inhibitor atinvicitinib is a potent and highly selective inhibitor of JAK1. Vet Dermatol. 2026;0:17. https://doi.org/10.1111/vde.70046 2. Kowalski T, Prohaczik A, Locke K, et al. The second generation Janus kinase inhibitor atinvicitinib significantly reduces pruritus 2-4 hours after dosing dogs in a canine interleukin-31 model. Vet Dermatol. 2026;0:17-18. https://doi.org/10.1111/vde.70046 S4 NUMELVI® 4,8 mg tablets, Reg. No. 25/13/01 (Act 101/1965). Each tablet contains Atinvicitinib 4,8 mg S4 NUMELVI® 7,2 mg tablets, Reg. No. 25/13/02 (Act 101/1965). Each tablet contains Atinvicitinib 7,2 mg S4 NUMELVI® 21,6 mg tablets, Reg. No. 25/13/03 (Act 101/1965). Each tablet contains Atinvicitinib 21,6 mg S4 NUMELVI® 31,6 mg tablets, Reg. No. 25/13/04 (Act 101/1965). Each tablet contains Atinvicitinib 31,6 mg Intervet South Africa (Pty) Ltd | Reg. No. 1991/006580/07 20 Spartan Road, Spartan, 1619, RSA | Private Bag X2026, Isando, 1600, RSA | Tel: +27 (0)11 923 9300 | E-mail: msdahza@msd.com | E-mail: salesordersmsd@msd.com www.msd-animal-health.co.za | ZA-NUM-260700001 © 2026 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. At least 10X more selective for JAK11* Starts relieving itch within 2-4 hours2** Reassuring safety and efficacy Broadest weight and age rangesafe for dogs and puppies as young as 6 months of age & 2 kg Once daily dosing, at or within 30 minutes of feeding, from day 1
RkJQdWJsaXNoZXIy OTc5MDU=